KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biogen (BIIB) EBT Margin (2016 - 2025)

Biogen has reported EBT Margin over the past 17 years, most recently at 2.46% for Q4 2025.

  • Quarterly results put EBT Margin at 2.46% for Q4 2025, down 1433.0% from a year ago — trailing twelve months through Dec 2025 was 15.74% (down 396.0% YoY), and the annual figure for FY2025 was 15.74%, down 396.0%.
  • EBT Margin for Q4 2025 was 2.46% at Biogen, down from 21.99% in the prior quarter.
  • Over the last five years, EBT Margin for BIIB hit a ceiling of 54.66% in Q3 2022 and a floor of 5.58% in Q3 2023.
  • Median EBT Margin over the past 5 years was 18.04% (2023), compared with a mean of 19.86%.
  • Biggest five-year swings in EBT Margin: soared 4418bps in 2022 and later crashed -6024bps in 2023.
  • Biogen's EBT Margin stood at 14.81% in 2021, then surged by 60bps to 23.73% in 2022, then plummeted by -49bps to 12.22% in 2023, then decreased by -3bps to 11.88% in 2024, then plummeted by -121bps to 2.46% in 2025.
  • The last three reported values for EBT Margin were 2.46% (Q4 2025), 21.99% (Q3 2025), and 28.12% (Q2 2025) per Business Quant data.